# DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes

> **NCT06875193** · PHASE4 · RECRUITING · sponsor: **Dong Wha Pharmaceutical Co. Ltd.** · enrollment: 196 (estimated)

## Conditions studied

- Type2diabetes

## Interventions

- **DRUG:** DW6012(Dasidiem tab. 10/100mg)

## Key facts

- **NCT ID:** NCT06875193
- **Lead sponsor:** Dong Wha Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-28
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06875193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06875193, "DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06875193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*